|
News for Healthier Living
Adding Immune Checkpoint Inhibitor to Standard Chemotherapy Regimen Improves Outcomes in Stage 3 Colon Cancer, Study Finds
Combining standard adjuvant chemotherapy with an immune checkpoint inhibitor (atezolizumab) leads to a significant improvement in disease-free survival in a subset of patients with stage 3 colon cancer that is deficient in DNA mismatch repair (dMMR), Dana-Farber Cancer Institute investigator Dr. Jeffrey Meyerhardt and his colleagues report at the 2025 American Society of Clinical Oncology (ASCO) meeting.
June 1, 2025
June 14 2025June 13 2025June 12 2025June 11 2025June 10 2025June 9 2025June 8 2025June 7 2025June 6 2025June 5 2025June 4 2025June 3 2025June 2 2025June 1 2025
|
|
|
|
|